As Cilta-Cel’s Big Day Approaches, Legend Looks Beyond Myeloma
Company To Go Solo With T-Cell Lymphoma Program
CEO Ying Huang talked about the biotech’s plans for CAR-T therapies after its J&J-partnered program.
You may also be interested in...
Bluebird Spinoff 2seventy Bio Gets Its Own Wings
The formal split between the companies had been in the works since January, with 2seventy set to take over oncology operations while bluebird focuses on gene therapies.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: US tax policies challenge pharma; J&J’s long-time R&D head to retire; Legend Biotech’s CEO talks about plans; BMS disappointment in ulcerative colitis; and another gene therapy partnership for Takeda.
COVID-19-Induced Actemra Shortage Causes Headaches For CAR-T Centers
While some cancer centers report sufficient stocks of the drug, they have already been turning to potential alternatives due to supply issues that could last for weeks or months.